BRIEF—Gilead quietly adds 5% to prices

US biotech giant Gilead Sciences is raising US list prices on 14 of its top-selling medicines by nearly 5%, according to BioPharma Dive.

The rises come at a time when drugmakers are under pressure to freeze prices or limit rises in the USA, but they are less significant increases than those levied by Gilead in the previous two years.

Gilead failed to respond to The Pharma Letter’s requests for a comment to confirm or explain the price rises.